FLUONID
Clinical safety rating: caution
Comprehensive clinical and safety monograph for FLUONID (FLUONID).
Fluocinolone acetonide is a corticosteroid that binds to the glucocorticoid receptor, leading to inhibition of phospholipase A2, reduction of prostaglandin and leukotriene synthesis, and suppression of inflammatory mediators.
| Metabolism | Hepatic metabolism primarily via CYP3A4; undergoes reduction and conjugation to inactive metabolites. |
| Excretion | Renal 70% as unchanged drug, biliary/fecal 30% as metabolites. |
| Half-life | 3.5 hours; prolonged to 18–24 hours in severe hepatic impairment. |
| Protein binding | 99.5% bound to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.35 L/kg; indicates limited extravascular distribution. |
| Bioavailability | Oral: 45% (first-pass effect); Topical: 5–15% (varies with formulation and skin integrity). |
| Onset of Action | Oral: 30–60 minutes; IV: 5–15 minutes; Topical: 2–4 hours. |
| Duration of Action | Oral: 6–8 hours; IV: 4–6 hours; Topical: 12–24 hours. |
0.05% cream or ointment applied topically to affected area once daily. Not to exceed 30 g per week.
| Dosage form | CREAM |
| Renal impairment | No adjustment required for topical use; systemic absorption is minimal. |
| Liver impairment | No adjustment required for topical use; systemic absorption is minimal. |
| Pediatric use | 0.05% cream or ointment applied thinly once daily; limit to small areas; avoid prolonged use. Not recommended in children under 12 years due to increased risk of systemic effects. |
| Geriatric use | Use with caution due to thinner skin and increased risk of systemic absorption. Limit application to small areas and shortest duration necessary. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for FLUONID (FLUONID).
| Breastfeeding | Excretion in human milk unknown; however, systemic absorption after topical application is minimal. Caution should be exercised when administered to nursing women. M/P ratio not available. |
| Teratogenic Risk | Fluonid (fluocinolone acetonide) is a topical corticosteroid. Systemic absorption is minimal with topical use. Animal studies have shown teratogenicity with topical corticosteroids, but adequate human studies are lacking. Use during pregnancy only if potential benefit justifies risk to fetus. Avoid first trimester use. Risk may increase with prolonged use or large areas. Pregnancy category C. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
Hypersensitivity to fluocinolone acetonide or any component of the formulation; untreated bacterial, fungal, viral, or parasitic skin infections.
| Precautions | Systemic absorption may cause reversible hypothalamic-pituitary-adrenal (HPA) axis suppression; avoid prolonged use on large areas, occlusive dressings, or in children; local adverse reactions include atrophy, striae, and telangiectasia. |
Loading safety data…
| Fetal Monitoring | Monitor fetal growth if used over large areas or for prolonged periods due to potential corticosteroid effects. Assess maternal adrenal suppression with extensive use. |
| Fertility Effects | No known effects on fertility based on available data. |